Women's Health MRI


Prospective MRI Study Reveals Impact of Opioid Exposure on the Fetal Brain

September 30, 2022

Researchers found that in utero opioid exposure resulted in seven out of 14 2D biometric measurements of the fetal brain being smaller on magnetic resonance imaging (MRI) scans in comparison to fetuses without opioid exposure.

MRI Deep Learning Software from GE Healthcare Gets Expanded FDA Clearance

September 29, 2022

AIR Recon DL, a deep learning-based image reconstruction software, will now be available with 3D sequences as well as PROPELLER motion-insensitive sequences on magnetic resonance imaging (MRI) scanners from GE Healthcare.

A Closer Look at Ultrasound and MRI Alternatives for Head and Neck Imaging

September 29, 2022

In light of recent shortages of iodinated contrast media, researchers from Australia suggest in a new publication that ultrasound and magnetic resonance imaging (MRI) can be viable first-line imaging options for a number of non-urgent presentations of the head and neck.

What a New Meta-Analysis Reveals About Breast Density, Mammography and MRI Screening

September 28, 2022

Assessing data from 386,590 women, researchers noted that women with extremely dense breast tissue have more than double the risk for breast cancer in comparison to women with average breast density and nearly four times the risk of women with extremely fatty breast tissue.

FDA Approves New MRI Contrast Agent Gadopiclenol

September 22, 2022

Requiring only half of the gadolinium dose of current non-specific gadolinium-based contrast agents (GBCAs), gadopiclenol can be utilized with magnetic resonance imaging (MRI) to help detect lesions with abnormal vascularity in the central nervous system and other areas of the body.

Post-Vaccine Axillary Lymphadenopathy: What a New Chest MRI Study Reveals

September 19, 2022

In a new study looking at the development of axillary lymphadenopathy after a second dose of COVID-19 vaccination, researchers found that those who had the Moderna COVID-19 vaccine were 21 percent more likely to have the post-vaccine side effect in comparison to those who had the Pfizer-BioNtech COVID-19 vaccine.